<DOC>
	<DOCNO>NCT01464905</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy NU100 patient relapse remit multiple sclerosis ( RRMS ) compare placebo active comparator . The primary clinical objective select Phase 3 study , cumulative number new combine unique active lesion ( CALs ; define new gadolinium T1-weighted lesion non-enhancing new newly enlarge T2-weighted lesion ) magnetic resonance imaging ( MRI ) scan course 4 12 month treatment demonstrate superiority NU100 placebo non-inferiority NU100 Betaferon® , respectively .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety NU100 Patients With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Patients eligible participate study follow criterion meet screen ( V1 ) baseline ( V0 ) : 1 . Female male patient , age 18 60 year , inclusive 2 . Signed dated statement inform consent 3 . Diagnosis RRMS accord McDonald 's Criteria revision 2010 ( Polman et al. , 2011 ) 4 . Interferon ( IFN ) beta1b naïve 5 . Expanded Disability Status Scale ( EDSS ) score &lt; 5.5 6 . At least 1 documented relapse past year ( define appearance new clinical sign/symptom [ one stable least 30 day ] persist minimum 24 hour absence fever ) subclinical sign/symptom ( define Gdenhancing lesion new T2 lesion demonstrate MRI examination prior MRI complete within 1 year screen MRI ) . The Screening ( V1 ) MRI use determination . 7 . No relapse 4 week prior screen visit ( V1 ) . 8 . Must clinically stable improve neurological state 4 week precede screen visit ( V1 ) . Patients meet follow exclusion criterion screen ( V1 ) baseline ( V0 ) enrol study : 1 . Relapse baseline visit ( V0 ) occur within 4 week prior screen visit ( V1 ) 2 . Intake glatiramer acetate within 3 month prior screen ( V1 ) visit 3 . Intake previous immunotherapy immunosuppressant treatment , within 4 month prior screen ( V1 ) visit 4 . Intake previously receive therapy cladribine alemtuzumab 5 . An active viral , bacterial , systemic fungal infection within 1 week baseline ( V0 ) 6 . Use systemic steroid within 3 week prior screen ( V1 ) MRI 7 . Progressive disease 8 . Level liver enzymes 2.5 x upper limit normal 9 . Abnormal renal function ( estimate Glomerular Filtration Rate [ eGFR ] &lt; 60 ml/min/1.73 m2 ) 10 . Positive serology history Hepatitis B , C , human immunodeficiency virus ( HIV ) 11 . Serious acute coronary disease , define least 1 follow condition : Clinical symptom ischemic heart disease ST elevation depression &gt; 2 mm electrocardiogram ( ECG ) Clinical symptom cardiac failure and/or current medical treatment cardiac failure Severe ventricular arrhythmia ( frequent premature ventricular beat ) Atrioventricular block third level 12 . Chronic use nonsteroidal antiinflammatory drug 13 . History follow : Severe depression suicide attempt Uncontrolled seizure disorder Cancer , exclude adequately treat basal cell carcinoma skin adequately treat situ carcinoma cervix Previous contrast reaction gadolinium contraindication MRI ( e.g. , metal eye , pacemaker , aneurysm clip ) 14 . Allergy human albumin mannitol 15 . Excessive alcohol use illicit drug use 16 . Women breast feeding , pregnant , plan become pregnant , unwilling use effective birth control method study 17 . Medical , psychiatric , condition compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study 18 . Participation study involve investigational market product , concomitantly within 30 day prior entry study Current participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>RRMS</keyword>
</DOC>